Nuodil (Tiotropium)

Tiotropium, the active ingredient in Nuodil, is a long‑acting muscarinic antagonist presented as a inhalation powder for respiratory use. It is indicated for maintenance therapy in chronic obstructive pulmonary disease and helps improve lung function in adult patients. GNH USA supplies Nuodil as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Tiotropium is a bronchodilator that works within the airway smooth‑muscle pathway to provide long‑lasting relief in obstructive lung disease. - Chronic obstructive pulmonary disease (COPD): improves airflow and reduces exacerbations. - Asthma (as add‑on therapy): enhances control when inhaled corticosteroids are insufficient. - Chronic bronchitis: decreases symptom burden and improves exercise tolerance.

Adverse reactions to inhaled tiotropium are generally mild to moderate and vary with individual sensitivity.

Common Side Effects: - Dry mouth: mild dryness of the oral cavity. - Cough: transient irritation after inhalation. - Throat irritation: mild soreness or tickle. - Upper respiratory tract infection: occasional viral‑like symptoms. - Headache: mild, self‑limiting. - Constipation: occasional bowel habit change.

Serious or Rare Side Effects: - Paradoxical bronchospasm: sudden worsening of breathing. - Angioedema: swelling of lips, tongue or airway. - Severe allergic reaction: rash, hives, or anaphylaxis. - Urinary retention: difficulty emptying the bladder. - Tachycardia: rapid heart rate not related to other causes.

Before initiating therapy, clinicians should evaluate patient history and comorbid conditions. - Assess renal function: dose adjustment may be required in severe impairment. - Review cardiovascular status: monitor for tachycardia or arrhythmias. - Check for urinary tract obstruction: risk of retention may increase. - Evaluate for hypersensitivity: avoid if known allergy to tiotropium or excipients. - Store at below 25°C: keep in the original packaging, protect from moisture and heat.

Tiotropium has a limited interaction profile, but certain drugs may modify its safety or efficacy.

Major Interactions (Avoid): - Anticholinergic overload: concurrent use with other long‑acting antimuscarinics may increase systemic anticholinergic effects. - Beta‑agonist overuse: high‑dose LABA combined with tiotropium can heighten cardiovascular risk.

Moderate Interactions (Monitor Closely): - Diuretics: may exacerbate dry mouth and urinary retention. - Potassium‑sparing diuretics: monitor serum potassium if combined with inhaled corticosteroids. - CYP3A4 inhibitors: rare metabolic interaction, observe for increased systemic exposure.